Evidence-based medicine or ORIGIN study lessons (Outcome Reduction with Initial Glargine INtervention)
AbstractOne of the most significant and global studies of the last decade is ORIGIN (Outcome Reduction with Initial Glargine INtervention-reducing the effects of diabetes mellitus by early administration of insulin glargine) -a comparison of the treatment with Lantus (insulin glargine 100 U/ml) with standard hypoglycemic therapy in terms of time the development of the first major cardiovascular complication. The results obtained in a long-term study proved the effectiveness of insulin therapy (glargine 100 U/ml), cardio and cancer safety.
Keywords:diabetes mellitus, insulin therapy, insulin Glargine, evidence-based medicine, ORIGIN
For citation: Ametov A.S., Doskina E.V. Evidence-based medicine or ORIGIN study lessons (Outcome Reduction with Initial Glargine INtervention). Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2019; 8 (4): 21-6. doi: 10.24411/2304-9529-2019-14003 (in Russian)
Литература/References
1. Sackett D. L., Rosenberg W. M., Gray J., et al Evidence based medicine: what it is and what it isn’t. BMJ. 1996; 312 (7023): 71.
URL: https://www.bmj.com/content/312/7023/71
DOI: 10.1136/bmj.312.7023.71
2. ORIGIN Trial Investigators. Diabetes Care. 2016; 39: 709-16.
URL: https://www.ncbi.nlm.nih.gov/pubmed/26681720
DOI: 10.2337/dc15-1676
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-53.
URL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)07019-6/fulltext
DOI: https://doi.org/10.1016/S0140-6736(98)07019-6
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352: 854-65.
URL: https://www.ncbi.nlm.nih.gov/pubmed/9742977
DOI: https://doi.org/10.1016/S0140-6736(98)07037-8
5. The ADVANCE Collaborative Group. N Engl J Med. 2008; 358: 2560-72.
URL: https://www.ncbi.nlm.nih.gov/pubmed/18539916
DOI: 10.1056/NEJMoa0802987
6. ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease - preterax and diamicron MR controlled evaluation. Diabetologia. 2001; 44: 1118-20.
URL: https://www.ncbi.nlm.nih.gov/pubmed/11596665
DOI: 10.1007/s001250100612
7. Miriam E Tucker. New VADT Data: Hypoglycemia Is a Risk Factor for CVD in Some//2016,
URL: https://www.medscape.com/viewarticle/857853